There's a new contraceptive pill on the block - Zoely. Picking up where Yasmin left off, it's from the latest generation of oral contraceptives and experts hope it could be the answer for thousands of ...

Teva Pharmaceuticals Europe BV, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. , and MSD (known as Merck in the United States and Canada) , today announced that ZOELY(TM), a new oral ...

LONDON--(BUSINESS WIRE)--For Medical & Business/Industry Trade Media and Investors outside the US and Canada Only Theramex, a global women’s health company, today announced that the safety results ...

LONDON, Jan. 22, 2020 /PRNewswire/ -- Theramex today announced that it has entered into a definitive agreement to acquire further rights to Zoely®, a patented oral contraceptive, from MSD, the ...

calculated as 0.38 (upper limit 95% confidence interval 0.97). The PI calculation was based on pregnancies that occurred after the onset of treatment and within two days after the last pill intake. In ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) announced today that its new oral contraceptive, ZOELY ™ (NOMAC/E2 –nomegestrol acetate 2.5 mg/17β-estradiol 1.5 mg), has ...

Teva Pharmaceutical Industries Ltd announced that its new oral contraceptive, Zoely (NOMAC/E2 Cnomegestrol acetate 2.5 mg/17-estradiol 1.5 mg), has received a Marketing Authorization in the European ...

Results from large-scale real-world safety study for oral combination contraception pill, Zoely® (NOMAC-E2), submitted to European Medicines Agency LONDON, UK – 27 April 2021. Theramex, a global ...

LONDON, Jan. 22, 2020 /PRNewswire/ -- Theramex today announced that it has entered into a definitive agreement to acquire further rights to Zoely®, a patented oral contraceptive, from MSD, the ...